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ABSTRACT 
Background: The incidence of non-ST elevation myocardial infarction (NSTEMI) is 
increasing. While life-threatening ventricular arrhythmias have been well-documented in 
patients with ST elevation myocardial infarction (STEMI), their incidence and 
importance in NSTEMI have not been examined in similar detail. We examined the 
incidence, predictors and mortality rates of ventricular arrhythmias in a cohort of 
NSTEMI patients undergoing an early invasive strategy. 
Methods:  Consecutive patients admitted with NSTEMI who underwent cardiac 
catheterization within 48 hours of admission were identified via chart review. Presence 
and type of ventricular arrhythmias and 30 day mortality were recorded. Malignant 
arrhythmias were defined as sustained ventricular tachycardia (VT; >100 beats/minute 
lasting >30 seconds) or fibrillation (VF). Clinical risk factors, laboratory values, findings 
on electrocardiogram, echocardiogram, cardiac catheterization, and revascularization 
procedure data were recorded. 
Results: VT/VF occurred in 21 (7.6%) of 277 NSTEMI patients.  Sixty percent of these 
events occurred within the first 48 hours following hospital admission, with a median 
occurrence at 72 hours. Twelve (4.3%) required defibrillation. Troponin levels were 
higher and left ventricular ejection fraction lower in the VT/VF group. Multivariable 
analysis also identified the presence of left bundle branch block and need for urgent 
coronary artery bypass grafting as significant predictors of malignant ventricular 
arrhythmias. Thirty day mortality was significantly higher in NSTEMI patients with 
malignant ventricular arrhythmias than without (38 versus 3%; p<0.001). 
Conclusion: Despite early invasive strategy, malignant ventricular arrhythmias are 
frequent in NSTEMI patients and are associated with increased 30 day mortality.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Acute myocardial infarction patients are prone to developing life-threatening ventricular 
arrhythmias in the early phase of their event. Ischemia has a rapid and profound effect on 
the electrophysiological properties of the myocyte. Changes in the resting membrane 
potential and ionic fluxes during the action potential lead to alterations in conduction, 
refractoriness, and automaticity of cardiac muscle cells, all of which contribute to the 
occurrence of arrhythmias in these patients 1,2.  The incidence of ventricular arrhythmias 
in acute myocardial infarction is reported to be between 2 and 20%3,4,5,6, with the highest 
incidence noted in patients with ST elevation myocardial infarction (STEMI) receiving 
thrombolytic therapy. In STEMI, ventricular arrhythmias predict higher mortality. 
However, there is scant data regarding the risk of ventricular arrhythmias in patients with 
non-ST elevation myocardial infarction (NSTEMI).  
      
The incidence of NSTEMI has nearly doubled since the introduction cardiac troponins for 
the diagnosis of acute myocardial infarction7,8,9. The risk of acute life-threatening 
arrhythmias in these cases may differ from that in patients with STEMI, and thus the 
level of monitoring required may be different. In most hospitals, all patients with AMI 
are placed in coronary care units, irrespective of the type of infarction, for continuous 
electrocardiographic and hemodynamic monitoring.  
 Few studies have investigated the risk of malignant arrhythmias in patients with 
NSTEMI.  A study from Europe found the rate of malignant ventricular arrhythmias in 
NSTEMI patients to be 2.6%. The only predictor for their occurrence was found to be the 
white cell count at admission10. In a pooled analysis of several studies, the incidence of 
ventricular arrhythmias in patients with non-ST elevation acute coronary syndromes was 
found to be 2.1%. Several predictors were identified, including hypertension, chronic 
obstructive lung disease, prior MI and ST changes at presentation11. 
 
We aimed to study the incidence of life-threatening ventricular arrhythmias and their risk 
factors in patients with NSTEMI treated with an early invasive strategy. Our goal was to 
determine if it was possible to admit selected patients with NSTEMI to less monitored 
settings than the coronary care unit based on the overall incidence of and risk factors for 
ventricular arrhythmias.  
 
Methods: 
This was a retrospective cohort study of consecutive patients with NSTEMI, as defined 
by the current American College of Cardiology /American Heart Association guidelines12 
who underwent cardiac catheterization within 48 hours of admission, between January 
2005 and July 2007. Patients who did not undergo catheterization within 48 hours were 
excluded to avoid including patients with non-acute coronary syndrome troponin 
elevations and those with NSTEMI not considered catheterization candidates due to 
significant comorbidities. Demographics, cardiac risk factors, vital signs on admission, 
Killip class on admission, blood cell counts, basic metabolic profile, peak creatine 
phosphokinase, peak troponin I and electrocardiogram data were collected . Medications 
on admission and those administered during hospital stay were extracted from charts. 
Left ventricular ejection fraction (LVEF) and presence of segmental wall motion 
abnormalities were recorded from the echocardiogram. Coronary angiography findings 
were recorded as one, two or three vessel disease (defined as the number of major vessels 
with > 70% stenosis). Involvement of the left main coronary artery was noted separately.  
The Thrombolysis in Myocardial Infarction (TIMI) risk scores12 were calculated. 
Interventions performed, either percutaneous coronary intervention or coronary artery 
bypass grafting, were recorded. Thirty day mortality was acquired using the Social 
Security Death Index records. 
 
Sustained ventricular tachycardia (VT) was defined by the presence of a series of 
consecutive ectopic ventricular beats at a rate of >100 beats/minute lasting >30 seconds 
or lasting less than 30 seconds but producing hemodynamic compromise.  Nonsustained 
ventricular tachycardia was defined as ≥3 consecutive ventricular ectopic beats at a rate 
of >100 beats/minute lasting <30 seconds. Episodes of nonsustained VT were not 
included in the definition of malignant ventricular arrhythmias after myocardial 
infarction.   Ventricular fibrillation (VF) was defined as irregular electrocardiographic 
waves of inconsistent shape and unidentifiable QRS complexes accompanied by 
hemodynamic compromise requiring defibrillation. Cases of concomitant VT and VF 
were categorized as VF. Sustained VT and VF were grouped together as malignant 
ventricular arrhythmias.  
 
Data were analyzed using STATA 10 Software (StataCorp, College Station, TX). 
Categorical data were expressed as percentages and continuous data were expressed as 
mean ± standard deviation (SD).  Differences between the two groups were analyzed 
using Fisher’s exact test for categorical variables and two-sample t-test with equal 
variances for continuous variables. A stepwise multivariable logistic regression model 
was used to analyze variables that were statistically significantly associated with 
malignant ventricular arrhythmias on univariate analysis.  
 
 
Results: 
We studied 277 consecutive patients with NSTEMI treated with an early invasive 
strategy. Clinical characteristics are shown in Table 1. Malignant ventricular arrhythmias 
occurred in 21 (7.6%) patients. Non-sustained ventricular tachycardia identified in the 
chart occurred in another 17 (6.1%) patients. Sixty percent of patients with malignant 
ventricular arrhythmias had these events recorded within the first 48 hours of admission 
to the hospital. Three patients presented to the hospital with these arrhythmias. The 
median time for the occurrence of malignant ventricular arrhythmias was 72 hours. 
Twelve patients (57% of the malignant ventricular arrhythmia group; 4.3% of the total 
NSTEMI patients) required defibrillation.  
 
There were no statistically significant differences between NSTEMI patients with and 
without malignant ventricular arrhythmias with respect to age, hypertension, diabetes, 
smoking, or family history of coronary artery disease. At presentation, more patients with 
malignant ventricular arrhythmias had complaints of palpitations (33% vs. 14%, 
p=0.028). The distribution of Killip classes was similar in both groups, with the majority 
of patients being Killip class I. 
  
Among laboratory values, neither potassium nor magnesium levels were statistically 
different between the two groups. Mean values of CPK and troponin I, were significantly 
higher in the group with malignant ventricular arrhythmias (mean CPK; 838 vs. 362 
mg/dL, p<0.001, mean troponin I 19.8 vs. 9.1 ng/mL, p=0.016).  
 
Only one patient (5%) who developed malignant ventricular arrhythmia had a normal 
electrocardiogram at presentation, while 56 (22%) patients who did not have ventricular 
arrhythmias had normal presenting electrocardiograms (p= 0.045). The most frequent 
abnormality observed was T wave inversion, seen in 86% of patients with a malignant 
ventricular arrhythmia and 52% cases without (p=0.003). Thirty three percent of patients 
who had malignant ventricular arrhythmias had a left bundle branch block (LBBB) 
compared to 10% of those without (p=0.006). Other abnormalities, such as ST segment 
depression greater than 1 mm and Q waves, were not significantly different between 
groups. There was a non-significant trend of more frequent supraventricular arrhythmias 
in patients with malignant ventricular arrhythmias (29 vs.13%, p=0.051). 
 
 
On echocardiography, the mean left ventricular ejection fraction was significantly lower 
in the group with malignant ventricular arrhythmias (40 ± 13% vs. 50 ± 15%, p=0.003). 
A non-significant trend of more frequent regional wall motion abnormalities on 
echocardiography were seen in the malignant ventricular arrhythmia group (76% vs. 
56%, p=0.053).  
 
Coronary angiography revealed a similar proportion of patients with single, double or 
triple vessel disease in both groups. The TIMI risk score was not significantly different 
between groups. However the number of patients with ventricular arrhythmias 
undergoing coronary artery bypass grafting was significantly higher than that of patients 
without these arrhythmias (38% versus 14%, p=0.008).  
 Medications at admission were similar in both groups, as were medications administered 
during hospital stay with the exception of amiodarone (Table 2). Amiodarone was used 
more often in patients with ventricular arrhythmias (48% versus 6%; p<0.001). Seven 
patients (33%) with malignant ventricular arrhythmias were administered lidocaine.  
 
LVEF, LBBB on electrocardiogram, peak troponin I value, and need for urgent coronary 
artery bypass grafting were the variables entered in to a stepwise logistic regression 
analysis. Of these, LBBB and urgent coronary artery bypass grafting were found to be 
statistically significant predictors of patients having malignant ventricular arrhythmias 
(Table 3).  
 
Thirty day mortality was significantly higher in the malignant ventricular arrhythmia 
group (38% versus 3%, p<0.001). When thirty-day mortality was used as an outcome 
variable in a multivariable logistic regression analysis using other factors associated with 
a higher mortality in NSTEMI patients (LVEF, peak troponin I and chronic kidney 
disease), ventricular arrhythmias remained significantly predictive of mortality (odds 
ratio 15.38, 95% confidence intervals 4.31-54.96; Table 4). Interestingly, the mortality in 
the 6.1% of patients with non-sustained ventricular tachycardia was intermediate at 21%. 
 
Discussion: 
The risk of life-threatening ventricular arrhythmias in patients with NSTEMI treated with 
an early invasive strategy was 7.6% in this study. On multivariate analysis, risk factors 
identified for predicting their occurrence were LBBB and need for urgent coronary artery 
bypass surgery. NSTEMI patients who experienced malignant arrhythmias had a 
significantly higher 30 day mortality compared to those who did not.  
 
The incidence of malignant ventricular arrhythmias was higher in our study than 
previously reported in patients with NSTEMI 10,11, 14.  Comparison of patient 
characteristics reveals that NSTEMI patients in the present inner-city hospital study had a 
higher incidence of cardiac risk factors, including hypertension, dyslipidemia, diabetes 
and family history of coronary artery disease, in addition to a higher incidence of 
previous myocardial infarction, as compared to the patient populations in these 
studies10,11,14. In contrast, the incidence of malignant ventricular arrhythmias in the 
NSTEMI population studied was lower than that seen in patients with STEMI in the 
Global Utilization of Streptokinase and TPA for Occluded coronary arteries (GUSTO-I; 
10.5%), the Global Use of Strategies to Open occluded coronary arteries (GUSTO III; 
7.3%), and the Euro Heart Survey of Acute Coronary Syndromes (10%) studies14. 
 
In the present study, the median time to development of malignant ventricular 
arrhythmias was 72 hours, comparable to 78 hours in a pooled analysis of four 
randomized trials of NSTEMI patients11. Only 60% of our patients had malignant 
ventricular arrhythmias recorded within the first 48 hours, whereas in most other studies, 
malignant ventricular arrhythmias were recorded in 70 to 90% cases within the first 48 
hours of presentation; the percentage is even higher in patients with STEMI10,11,14,15. 
 
Traditional risk factors for coronary artery disease and previous myocardial infarction, 
were not found to predict malignant ventricular arrhythmias. Other studies found 
different factors associated with the risk of malignant ventricular arrhythmias, including 
hypertension, chronic obstructive pulmonary disease, previous myocardial infarctions, 
heart failure, cardiogenic shock, and chronic kidney disease11,17. None of these factors 
were consistently observed across studies, suggesting relatively weak causality.  
 
Although low serum potassium and magnesium levels have been shown to be associated 
with an increased incidence of ventricular arrhythmias, there was no correlation in this 
study. This may be because we considered only the admission values for analysis, and it 
is likely that NSTEMI patients with hypokalemia and hypomagnesemia were 
aggressively treated. 
 
NSTEMI patients with higher CPK and troponin values and lower left ventricular 
ejection fractions (factors suggesting a larger infarct) were more likely to have malignant 
ventricular arrhythmias. This is similar to studies in STEMI patients that have 
demonstrated a higher likelihood of developing ventricular arrhythmias with larger 
infarcts4,17,18. Larger infarctions are associated with early left ventricular dilatation and 
remodeling due to ventricular stretching and electromechanical feedback, thus producing 
a substrate capable of developing reentrant circuits for arrhythmia genesis 19,20.  
 Patients with LBBB on electrocardiogram were more likely to develop ventricular 
arrhythmias, similar to findings from other studies21, 22. The incidence of LBBB in 
patients with ventricular arrhythmias was higher in our study at 21% as opposed to 5-7 % 
in other studies10. This may be related to the higher prevalence of risk factors in our 
patients. The blocked bundle branch can provide a reentry circuit which, along with local 
ionic changes induced by ischemia and functional autonomic denervation, can lead to 
genesis of ventricular arrhythmias23,24. 
 
The TIMI risk score is widely used to risk-stratify patients with non-ST elevation acute 
coronary syndromes. In the present study, the mean TIMI scores did not differ between 
groups. This is not surprising given that none of the components of the TIMI score were 
significantly predictive of malignant ventricular arrhythmias in this study. Other studies 
have found the TIMI score to predict mortality but not the risk of arrhythmias10.  
 
Need for urgent coronary artery bypass grafting was found to be significantly associated 
with malignant ventricular arrhythmias. Oxygen-derived free radicals and transient 
calcium overload play important pathologic roles in arrhythmogenesis after cardiac 
surgery25. Although supraventricular arrhythmias and ventricular extrasystoles are far 
more common after coronary artery bypass grafting26, studies have reported a higher 
incidence of malignant ventricular arrhythmias27, 28. Potential reasons why malignant 
ventricular arrhythmias are more frequent in these patients could be that they were 
revascularized later than those undergoing percutaneous coronary intervention, and may 
have had greater amounts of ischemic myocardium.  
 
 
To conclude, the significant risk of malignant ventricular arrhythmias in NSTEMI found 
in the present study supports the current practice of monitoring these patients in the 
coronary care unit early in the course of their illness. Since mortality associated with 
these arrhythmias is high, we need to identify factors predictive of their development 
such as those found in our study. Prospective studies to develop risk scores predicting 
ventricular arrhythmias could provide triage algorithms for determining levels of 
care/monitoring during hospitalization. 
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Table 1: Clinical characteristics of the two NSTEMI groups 
 
Patient characteristic With VT/ VF 
    (n=21) 
Without VT/VF 
    (n=256) 
P value 
Age (mean ± SD) 63.5 ± 0.8 66.3 ± 2.8 0.816 
Gender 
   Male 
   Female 
 
  9 (42.8%) 
12 (57.1%) 
 
134 (52.3%) 
122 (47.7%) 
 
0.271 
Race 
   Caucasian 
   African-American 
   Hispanic  
   Others 
 
  4 (19.1%) 
16 (76.2%) 
  0 (0.0%) 
  1 (4.8%)  
 
  65 (25.4%) 
154 (60.2%) 
  28 (10.9%) 
    9 (3.5%) 
   
 
0.268 
Past Medical History 
   Hypertension 
   Diabetes Mellitus 
   Dyslipidemia 
   Coronary Artery Disease 
   Myocardial Infarction 
   Congestive Heart Failure 
   Arrhythmias 
   Chronic kidney disease 
   Prior angioplasty 
   Prior coronary artery bypass 
grafting 
   Obesity 
   Smoking 
   Chronic obstructive  pulmonary 
disease 
 
 
18(85.7%) 
 7 (33.3%) 
13 (61.9%) 
12 (57.1%) 
  9 (42.9%) 
  6 (28.6%) 
  3 (14.3%) 
  7 (33.3%) 
  5 (23.8%) 
  1 (4.8%) 
   
   2 (9.5%) 
 11(52.4%) 
   1(4.7%) 
 
210(82.0%) 
109(42.6%) 
141(55.1%) 
121(47.3%) 
 12 (57.1%) 
 35 (13.7%) 
 20 (7.8%) 
 86 (33.6%) 
 64 (25.0%) 
 37(14.5%) 
  
 55(21.5%) 
138(53.9%) 
  34(13.3%) 
 
 
0.472 
0.279 
0.356 
0.260 
0.549 
0.071 
0.347 
0.594 
0.571 
0.184 
 
0.152 
0.535 
0.491 
 
Chief Complaints 
   Chest Pain 
   Dyspnea 
   Palpitations 
 
16 (76.1%) 
10 (47.6%) 
 7 (33.3%) 
 
220 (85.9%) 
139 (54.3%)  
  36 (14.1%) 
 
0.182 
0.357 
0.028 
Systolic Blood Pressure (mm Hg) 
Diastolic Blood Pressure(mm Hg) 
137 ± 31 
 77 ± 23 
143 ± 28 
 78 ± 17 
0.151 
0.345  
Laboratory values 
   Hemoglobin 
   White cell count 
   Creatinine 
   Potassium 
   Magnesium 
   Creatine Phosphokinase 
   Troponin I (peak) 
 
TIMI Score (mean) 
 
Killip Class on Admission 
                  I 
                 II 
                III 
                IV 
 
 
11.4 ± 0.3 
  9.9 ± 0.9 
  1.4 ± 0.7 
  4.4 ± 0.1 
  2.1 ± 0.1 
838.3 ± 939.2 
 19.8 ± 29.2 
 
   5 
 
 
 17(81.0%) 
  1(4.8%) 
  2(9.5%) 
  1(4.8%) 
 
 
12.1 ± 0.1 
  8.7 ± 0.2 
  1.6 ± 2.2  
  4.3 ± 0.1 
  1.9 ± 0.0 
361.9 ± 499.6 
  9.1 ± 20.9 
 
     4 
 
 
224(87.5%) 
  18(7.0%) 
  12(4.7%) 
    2(0.8%) 
  
 
0.052 
0.104 
0.289 
0.745 
0.949 
<0.001 
0.016 
 
0.085 
 
 
0.185 
Electrocardiographic changes 
    Normal EKG 
    ST  depression > 1mm 
    T wave inversion 
    Q wave 
    Left bundle branch block 
    Supraventricular arrhythmia 
     
 
  1 (4.8%) 
  9 (42.9%) 
 18 (85.7%) 
   3 (14.3%) 
   7 (33.3%) 
   6 (28.6%) 
 
   56 (21.9%) 
   98 (38.3%) 
 134 (52.3%) 
   19 (7.4%) 
   26 (10.2%) 
   32 (12.5%) 
 
0.045 
0.423 
0.003 
0.226 
0.006 
0.051 
Echocardiographic parameters 
   Left Ventricular Ejection  
Fraction 
   Segmental Wall Motion 
Abnormailty 
 
 
40.0 ± 12.9 
  
16 (76.3%) 
 
 
49.9 ± 14.7 
 
141 (55.7%) 
 
 
0.003 
 
0.053 
Presence of NSVT    3 (14.3%)   14 (5.5%) 0.128 
 
Cardiac Catheterization 
   Normal angiogram 
   One-vessel disease 
   Two-vessel disease 
   Three-vessel disease 
 
 
    
   1 (4.8%) 
   5 (23.8%) 
   6 (28.6%) 
   9 (42.9%) 
  
 
   
  22 (8.6%)   
  64 (25.0%) 
  66 (25.8%) 
104(40.6%) 
 
 
0.462 
0.571 
0.477 
0.507 
Intervention 
    PCI with stent placement 
    Coronary artery bypass grafting 
 16 (17.2%) 
   8 (38.1%) 
   8 (38.1%) 
170 (66.4%) 
139 (54.3%) 
  35 (13.7%) 
0.254 
0.115 
0.008 
Mortality at 30 days    8 (38.1%)     8 (3.1%) <0.001 
 
Table 2: Medical treatment of patients in the two groups 
 
Medication    With VT/VF 
        (n=21) 
Without VT/VF 
      (n=256) 
P value 
Medications at admission 
    Aspirin 
    Clopidogrel 
    Beta-blocker 
    ACE-inhibitor 
    Calcium-channel   
blocker 
    Statins 
    Diuretics 
    Nitrates   
      
 
        12 (57.1%) 
          5 (23.8%) 
          9 (42.9%) 
        13 (61.9%) 
          8 (38.0%) 
 
        12 (57.1%) 
          7 (33.3%) 
          4 (19.1%) 
 
     123 (48.1%) 
       62 (24.2%) 
     127 (49.6%) 
     123 (48.0%) 
       62 (24.2%) 
 
    143 (55.9%) 
      84 (32.8%)            
      55 (21.5%) 
 
  0.283 
  0.602 
  0.652 
  0.261 
  0.191 
 
  0.549 
  0.567 
  0.524 
Acute medications 
    Aspirin 
    Clopidogrel 
    GpIIb/IIIa antagonist 
    Heparin 
    Beta-blocker 
    Amiodarone 
    Lidocaine 
    
 
          21 (100%) 
          12 (57.1%)  
            7 (33.3%) 
          20 (95.2%) 
          19 (90.5%) 
          10 (47.6%) 
            7 (33.3%) 
 
     251 (98.1%) 
     183 (71.5%)  
       88 (34.4%) 
     249 (97.3%) 
     241 (94.1%) 
       14 (5.5%) 
         0 
 
  0.672 
  0.129 
  0.565 
  0.472 
  0.376 
 <0.001 
   ---- 
 
 
 
 
Table 3: Multivariable Regression Analysis for Malignant Arrhythmias 
 
 Odds Ratio (95% CI) P Value 
Troponin I value 1.01 (0.99-1.03) 0.098 
Left Bundle Branch Block 3.66 (1.28-10.44) 0.015 
Left Ventricular Ejection Fraction  0.96 (0.93-0.99) 0.023 
Coronary Artery Bypass Grafting 3.99 (1.46-10.91) 0.007 
 
 
 
 
Table 4: Multivariable Regression Analysis for Thirty-Day Mortality 
 
 Odds Ratio (95% CI) P Value 
Ventricular arrhythmias 15.38(4.31-54.96) <0.001 
Troponin I value 1.02 (1.00-1.04)   0.017 
Left Ventricular Ejection Fraction  0.96 (0.92-0.99)   0.048 
Chronic Kidney Disease 2.63 (0.77-8.99)   0.123 
 
 
 
 
 
